Fulgent Genetics came into this print on a rough streak, with the stock already down over the past month, and the earnings release has hit sentiment hard. Shares fell about 18% to US$16.55 as investors reacted to another quarter of sizeable losses and lower full year guidance.

The core story this time is margin and profit pressure. Fulgent Genetics posted a quarterly net loss of US$29.5m on US$85.4m of revenue and now expects a full year non GAAP loss per share in the low US$2 range. The market clearly moved to reprice that reality in one session.

Is Fulgent Genetics now priced for a long grind of losses, or has the selloff pushed NasdaqGM:FLGT into genuine bargain territory on sales multiples? Compare the stock against peers in…